Last updated: September 5, 2026
Naloxegol oxalate, marketed in the United States as Movantik, is an oral peripherally acting mu-opioid receptor antagonist for opioid-induced constipation in adults with chronic non-cancer pain. Its commercial trajectory has been shaped by three forces: declining and increasingly restricted opioid prescribing, competition from other PAMORAs, and a change in U.S. ownership from AstraZeneca to RedHill Biopharma. U.S. revenue reached a mature-product phase before RedHill’s financial distress disrupted commercial visibility. Naloxegol remains a small-molecule generic-entry product rather than a biosimilar asset, and its long-term value depends on formulary access, payer contracting, and the timing of generic competition.
What is naloxegol oxalate and how does Movantik work?
Naloxegol is a PEGylated derivative of naloxol, itself related to the opioid antagonist naloxone. The polyethylene glycol modification limits central nervous system penetration while preserving antagonism at peripheral mu-opioid receptors in the gastrointestinal tract.
Movantik is approved for opioid-induced constipation in adults with chronic non-cancer pain. The FDA-approved strengths are:
| Product |
Strength |
Dosage form |
U.S. indication |
| Movantik |
12.5 mg |
Tablet |
Opioid-induced constipation in adults with chronic non-cancer pain |
| Movantik |
25 mg |
Tablet |
Opioid-induced constipation in adults with chronic non-cancer pain |
The recommended starting dose is 25 mg once daily on an empty stomach. A 12.5 mg dose is used when tolerability or drug-interaction concerns warrant dose reduction. Strong CYP3A4 inhibitors are contraindicated, and dose adjustments are required with moderate CYP3A4 inhibitors and renal impairment. The label also warns against use in patients with known or suspected gastrointestinal obstruction because opioid receptor antagonism can increase the risk of gastrointestinal perforation in vulnerable patients.[1]
Movantik is differentiated from conventional laxatives because it directly addresses opioid-mediated gastrointestinal dysfunction. Its clinical and commercial competitors include methylnaltrexone, naldemedine, lubiprostone and prescription laxatives.
When did the FDA approve naloxegol and what regulatory exclusivity did it receive?
The FDA approved Movantik on September 16, 2014. The product received five years of new chemical entity exclusivity, subject to pediatric-exclusivity considerations and patent protection. NCE exclusivity therefore did not provide a durable barrier after the late 2010s.[2]
The FDA approval reflected clinical studies showing improved spontaneous bowel movement response compared with placebo in adults receiving opioids for chronic non-cancer pain. The approval did not cover opioid-induced constipation associated with active cancer pain or palliative care, where competing PAMORAs have different label positions.
FDA regulatory status
| Milestone |
Date |
| FDA approval of Movantik |
September 16, 2014 |
| Initial U.S. commercialization |
2014 |
| NCE exclusivity period |
Approximately 2014-2019 |
| U.S. rights transferred from AstraZeneca to RedHill |
2020 |
| RedHill entered Chapter 11 proceedings |
2023 |
Movantik is a prescription small-molecule drug. Biosimilar regulation does not apply. Future competition would proceed through an abbreviated new drug application, or ANDA, rather than through the FDA biosimilar pathway.
What patents protect naloxegol and when does exclusivity end?
Naloxegol’s U.S. intellectual-property protection is based on compound, PEGylated opioid-antagonist, formulation and method-of-use claims. The principal commercial risk is the expiration or invalidation of patents listed for the approved product, followed by ANDA approvals with Paragraph IV certifications.
Patent protection for Movantik has been associated with AstraZeneca patent families covering PEGylated opioid antagonists and their use in treating opioid-induced constipation. Patent terms depend on the particular patent, terminal disclaimers, patent-term adjustment and any pediatric extension. The effective generic-entry date cannot be determined from the FDA approval date alone.
What patent categories are relevant?
Composition and compound patents
Composition patents protect naloxegol or related PEGylated opioid-antagonist structures. These patents typically create the strongest barrier because an ANDA product must contain the same active ingredient and may be required to challenge the relevant patent directly.
Formulation patents
Formulation claims can cover tablet composition, stability, excipients, dosage strengths and release characteristics. Formulation patents generally provide narrower protection than composition patents because a generic manufacturer may design around individual excipient or process limitations.
Method-of-use patents
Method patents may cover administration of naloxegol for opioid-induced constipation, specific patient populations, dose regimens or treatment conditions. Their value depends on whether the FDA-approved use is sufficiently broad and whether a generic applicant can use a section viii label carve-out to omit the patented indication.
Manufacturing and process patents
Process patents may cover PEGylation, purification, crystallization, salt formation or production of naloxegol oxalate. These patents can raise development costs but usually do not prevent a generic applicant from pursuing a non-infringing manufacturing route.
The Orange Book remains the operative source for listed patents and pediatric-exclusivity information. Patent status should be assessed by product and patent number because a listed patent’s expiration date does not necessarily equal the earliest legally permissible generic launch date.[3]
What is the Orange Book status of Movantik?
Movantik’s Orange Book position is commercially important because listed patents determine the timing of ANDA certifications, potential Paragraph IV litigation and the possibility of a 30-month stay.
A generic applicant filing an ANDA may certify that:
- No relevant patent is listed.
- The patent has expired.
- The applicant will wait until patent expiration.
- The patent is invalid, unenforceable or will not be infringed.
A Paragraph IV certification gives the patent holder an opportunity to sue within 45 days. A timely infringement action can trigger a statutory 30-month stay of FDA approval, subject to court decisions and statutory exceptions.
Publicly available product information indicates that naloxegol’s principal composition and related protection reaches beyond the initial 2014-2019 exclusivity period. The commercial significance of each patent depends on current Orange Book listings, litigation outcomes and the ability of generic applicants to use label carve-outs. Patent expiration should therefore be evaluated at the patent-family level rather than by relying on a single headline date.
Which companies compete with naloxegol?
Naloxegol competes in the PAMORA and broader opioid-induced-constipation market.
| Product |
Active ingredient |
Company or principal commercial sponsor |
Administration |
Commercial position |
| Movantik |
Naloxegol |
AstraZeneca originally; RedHill in the U.S. |
Oral tablet |
Oral PAMORA with established market recognition |
| Symproic |
Naldemedine |
Shionogi |
Oral tablet |
Strong competitor in chronic opioid-induced constipation |
| Relistor |
Methylnaltrexone |
Bausch Health and related commercial partners |
Oral and injectable formulations |
Broader formulation options, including advanced illness use |
| Amitiza |
Lubiprostone |
Takeda historically; generic competition in some markets |
Oral capsule |
Non-PAMORA prescription alternative |
| Generic laxatives |
Multiple agents |
Numerous manufacturers |
Oral and rectal |
Low-cost first-line competition |
Naldemedine is a direct oral competitor with a similar target market. Relistor has an advantage in patient segments requiring injectable treatment or treatment associated with advanced illness. Naloxegol’s primary commercial advantages are oral dosing, physician familiarity and positioning within chronic non-cancer pain.
How did AstraZeneca and RedHill monetize Movantik?
AstraZeneca commercialized Movantik after the 2014 launch and later transferred U.S. rights to RedHill Biopharma. The transaction reflected AstraZeneca’s strategy of divesting mature or non-core products while RedHill sought to build a specialty pharmaceutical portfolio.
RedHill announced the acquisition of U.S. Movantik rights for approximately $52.5 million in upfront consideration, with potential additional payments tied to the transaction and product performance.[4] The deal transferred commercial responsibility and exposed RedHill to the product’s established revenue base, but also placed a mature branded drug inside a financially constrained company.
AstraZeneca’s public reporting showed Movantik revenue in the mature-product range before the transaction. RedHill subsequently reported Movantik revenue as one of its principal commercial assets.
What was the financial trajectory of Movantik?
Movantik’s financial trajectory can be divided into four stages:
| Stage |
Period |
Financial characteristics |
| Launch |
2014-2016 |
Prescription growth from a new branded PAMORA |
| Expansion and maturity |
2017-2019 |
Increasing payer and physician adoption, with competition from Relistor and Symproic |
| Ownership transfer |
2020 |
AstraZeneca monetized the U.S. asset; RedHill assumed commercialization |
| Financial stress and restructuring |
2021-2023 |
Product remained revenue-generating, but RedHill faced liquidity constraints and Chapter 11 proceedings |
AstraZeneca reported Movantik sales at approximately the low-hundreds-of-millions level in the years preceding divestiture, although the company’s reporting structure did not always provide a standalone multi-year product series. RedHill’s filings identified Movantik as a major source of product revenue after the acquisition, alongside Talicia and other assets.[5]
The asset’s economics were pressured by:
- declining chronic opioid exposure in some U.S. populations;
- formulary restrictions and prior authorization;
- payer preference for lower-cost laxatives;
- direct competition from Symproic and Relistor;
- promotional and distribution expenses;
- potential generic-entry risk;
- RedHill’s inability to sustain a stable commercial platform.
RedHill’s Chapter 11 filing materially changed the investment profile. A product can remain clinically useful and commercially recognized while its owner lacks the capital needed to support promotion, inventory, market access and field operations.
What generic launch risks exist for naloxegol?
Generic launch risk is substantial because naloxegol is an oral small molecule with a relatively straightforward dosage form. The principal barriers are patent litigation, regulatory review, manufacturing validation and commercial scale rather than biological complexity.
Likely generic-entry scenarios
At-risk launch
A generic manufacturer could launch before all asserted patents expire after prevailing in litigation, obtaining a favorable judgment, reaching a settlement or accepting infringement exposure. This scenario can produce rapid price erosion and inventory disruption.
Authorized generic or license settlement
The branded owner or a licensee could authorize a generic launch before patent expiry. This may preserve some value for the patent holder while limiting litigation costs.
Delayed entry after patent expiry
If composition or formulation patents remain enforceable, ANDA approval may occur before commercial launch, with market entry delayed until the relevant patent term ends.
Limited launch after a label carve-out
A generic could omit a patented method of use through a section viii statement, provided the remaining label is acceptable to the FDA and the omitted use does not create impermissible overlap.
Generic entry would likely reduce net sales rapidly because pharmacy benefit managers can substitute therapeutically equivalent products and demand substantial rebates. Oral tablets are particularly exposed to formulary substitution once multiple ANDA products are available.
How strong is the naloxegol patent estate?
The estate has moderate commercial strength rather than the profile of a biologic or complex drug-delivery product. Its strengths are the specialized chemistry, established clinical use and potential composition protection. Its weaknesses are the small-molecule nature of the product, the availability of alternative PAMORAs and the ability of generic companies to challenge or design around narrower formulation and process claims.
| Patent-estate factor |
Assessment |
| Active ingredient complexity |
Moderate |
| Manufacturing difficulty |
Moderate |
| Formulation differentiation |
Limited to moderate |
| Clinical switching costs |
Low to moderate |
| Biosimilar barrier |
Not applicable |
| ANDA vulnerability |
Material |
| Payer protection after generic entry |
Weak |
| Commercial durability without patents |
Limited |
The strongest remaining protection would come from enforceable composition claims. Method-of-use and formulation claims can extend the commercial runway but are more vulnerable to carve-outs, design-around strategies and litigation-based invalidity challenges.
What is the commercial outlook for naloxegol?
Naloxegol has a durable therapeutic niche but a constrained growth market. Opioid-induced constipation remains common among patients receiving chronic opioid therapy, yet the eligible population is affected by opioid-prescribing trends, payer controls and availability of inexpensive laxatives.
Near-term commercial value is concentrated in:
- maintaining preferred formulary status;
- retaining prescribers who prefer oral PAMORA therapy;
- reducing dependence on expensive direct-to-consumer promotion;
- securing distribution and reimbursement continuity;
- preserving value through a license, sale or authorized-generic strategy.
The greatest downside risk is a combination of generic entry and owner disruption. If generic competition arrives while commercial operations remain fragmented, net pricing could fall faster than prescription volume.
What patent litigation and settlement issues affect Movantik?
Paragraph IV litigation, if filed, would determine whether an ANDA applicant could launch before the asserted patent expiry dates. The relevant issues would include:
- validity of composition and PEGylated-antagonist claims;
- infringement by the proposed generic formulation;
- patent-term adjustment and pediatric exclusivity;
- whether use claims can be carved out;
- the scope of any settlement or licensed-entry agreement;
- whether a first Paragraph IV filer receives 180-day exclusivity.
Public commercial reporting does not establish a single, definitive generic-entry date for naloxegol. A transaction involving the product’s U.S. rights, RedHill’s restructuring and changes in ownership could also affect who has standing to enforce patents and who controls any settlement negotiations.
How does naloxegol compare with naldemedine and methylnaltrexone?
| Factor |
Naloxegol |
Naldemedine |
Methylnaltrexone |
| Main brand |
Movantik |
Symproic |
Relistor |
| Route |
Oral |
Oral |
Oral and injectable |
| Core market |
Chronic non-cancer pain |
Chronic opioid-induced constipation |
OIC, including advanced illness segments |
| Generic or patent risk |
Material |
Material |
Varies by formulation |
| Differentiation |
Oral PAMORA and established brand |
Oral PAMORA with competitive efficacy profile |
Injectable option and broader use settings |
| Commercial pressure |
Payer restrictions and potential generic entry |
Direct oral competition |
Formulation and segment-specific competition |
Movantik’s closest commercial comparison is Symproic because both are oral PAMORAs targeting chronic opioid-induced constipation. Relistor is less directly substitutable in every patient segment because its injectable presentation expands use beyond routine oral treatment.
Key takeaways
- Naloxegol oxalate is the active ingredient in Movantik, an oral PAMORA approved in 2014 for opioid-induced constipation in adults with chronic non-cancer pain.
- FDA NCE exclusivity expired approximately in 2019, leaving patent rights as the principal branded barrier.
- The product is a small molecule and faces ANDA-based generic risk, not biosimilar competition.
- AstraZeneca transferred U.S. rights to RedHill Biopharma in 2020 for reported upfront consideration of approximately $52.5 million.
- Movantik generated mature-product revenue in the low-hundreds-of-millions range before the rights transfer and became a major RedHill revenue source.
- RedHill’s 2023 Chapter 11 filing weakened commercial continuity and reduced transparency around future product ownership and promotion.
- The strongest protection is likely associated with composition and related chemical claims. Formulation, method-of-use and manufacturing claims provide narrower secondary protection.
- Generic entry would likely cause rapid price erosion because oral naloxegol can be substituted through pharmacy benefit management channels.
- The competitive set includes Symproic, Relistor, Amitiza and low-cost laxatives.
- The asset’s value is now driven more by patent timing, supply continuity, payer access and ownership execution than by prescription growth.
FAQs about naloxegol oxalate
Is naloxegol oxalate the same as Movantik?
Yes. Naloxegol oxalate is the active pharmaceutical ingredient used in Movantik tablets.
Is naloxegol a biologic drug?
No. Naloxegol is a chemically synthesized small molecule. Generic versions would use the ANDA pathway rather than the FDA biosimilar pathway.
Can naloxegol be used for cancer-related opioid-induced constipation?
Movantik’s FDA indication covers adults with chronic non-cancer pain. Use in cancer-related or palliative-care populations depends on clinical judgment and the applicable product labeling.
What is the main commercial threat to Movantik?
The principal threats are generic entry, payer preference for cheaper laxatives, direct competition from naldemedine and methylnaltrexone, and disruption caused by changes in product ownership.
Does patent expiry immediately eliminate Movantik revenue?
No. Patent expiry permits generic competition but does not guarantee immediate launch. Actual erosion depends on ANDA approval, litigation outcomes, settlement terms, supply capacity, payer substitution and the number of generic entrants.
References
- U.S. Food and Drug Administration. (2023). Movantik (naloxegol) prescribing information.
- U.S. Food and Drug Administration. (2014). FDA approves Movantik to treat opioid-induced constipation.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- RedHill Biopharma Ltd. (2020). RedHill Biopharma acquires U.S. rights to Movantik from AstraZeneca.
- RedHill Biopharma Ltd. (2023). Annual report and Form 10-K for the year ended December 31, 2022.
- AstraZeneca PLC. (2020). Annual report and Form 20-F.
